Brickell Biotech Inc (OQ:BBI)

Nov 13, 2019 04:05 pm ET
Brickell Bio Announces Third Quarter 2019 Financial Results and Provides Corporate Update
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial...
Oct 30, 2019 04:42 pm ET
Brickell Biotech Provides Update on Bodor Labs Complaint and Funding Agreement with NovaQuest
Brickell Biotech, Inc. (“Brickell”) (NASDAQ: BBI), a clinical-stage pharmaceutical company, today announced that it has initiated an arbitration proceeding pursuant to Article 9 of the License Agreement previously entered into between Bodor...
Sep 03, 2019 06:45 am ET
Brickell Biotech Completes Merger with Vical
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company, today announced the completion of its merger with Vical Incorporated (“Vical”), following approval by Vical’s stockholders. Brickell is expected to commence...